Renal function trajectories.

<p>Renal function trajectories.</p

Change in kidney function and the risk of death.

<p>Model 1 adjusted for age, race, gender, diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia and eGFR at time of cohort entry (T0). Reference group is patients with stable kidney function (eGFR slope).</p

Renal function trajectory phenotypes.

<p>Renal function trajectory phenotypes.</p

Demographic and clinical characteristics of those with improved, stable, and declining eGFR slope.

<p>Demographic and clinical characteristics of those with improved, stable, and declining eGFR slope.</p

Risk of death by trajectory.

<p>Model adjusted for age, race, gender, for age, race, gender, diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia, and eGFR at time of cohort entry (T0). Reference group is patients with stable kidney function before cohort entry (T0).</p

Risk of death of trajectory phenotypes.

<p>HIFNT = High Intercept and Fast Negative Trajectory includes trajectory F. HIPT = High Intercept Positive Trajectory and includes trajectory A and B; IIMNT = Intermediate Intercept Mild Negative Trajectory and includes trajectory C, and D; LIFNT = Low Intercept Fast Negative Trajectory and includes trajectory E and G; Model adjusted for age, race, gender, for age, race, gender, diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia, and eGFR at time of cohort entry (T0). Reference group is patients with stable kidney function before T0.</p

Demographic and clinical characteristics according to renal function trajectory.

<p>Demographic and clinical characteristics according to renal function trajectory.</p

Adjusted associations of improved eGFR slope, and declining eGFR slopes.

<p>Model adjusted for age, race, gender, diabetes mellitus, hypertension, cardiovascular disease, hyperlipidemia, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia, and initial eGFR. Reference group is patients with stable eGFR slope.</p

Cohort design and timeline.

<p>Cohort design and timeline.</p